Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone.
Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone.
复制标题
接受利培酮治疗的患有不同精神疾病的学龄前儿童的体重指数增加。
DOI：
10.1177/02698811211008592
复制
发表时间：
2021-09
影响因子：
4.1
通讯作者：
Barzilay, Ran
中科院分区：
文献类型：
--
作者：
Avrahami, Matan;Peskin, Miriam;Moore, Tyler;Drapisz, Adi;Taylor, Jerome;Segal-Gavish, Hadar;Balan-Moshe, Livia;Shachar, Issac;Levy, Tomer;Weizman, Abraham;Barzilay, Ran
利培酮在学龄前儿童中的使用正在增加，对不良代谢后果的担忧日益增加。关于学龄前儿童利培酮相关体重增加的纵向数据很少。我们的目的是评估与利培酮治疗学龄前儿童相关的体重指数（BMI）的变化。我们分析了141名接受精神病治疗的学龄前儿童（112名男孩，29名女孩）的自然纵向数据。基线时的平均患者年龄为5.0岁（SD=0.8），平均随访期为1.3年（SD=0.8），每个患者的平均BMI测量值>8。我们研究了利培酮暴露（n=78）对年龄和性别标准化BMI（BMI Z评分）的影响，采用随机受试者截取混合模型来解释重复测量，协变多个混杂因素，包括人口统计学，兴奋剂治疗和精神病诊断。我们采用类似的模型来研究剂量和持续时间的影响。利培酮治疗与BMI增加显著相关（暴露效应量=0.45 SD（SE=0.06），t（949）=7.7，p<0.001），与刺激性暴露和其他混杂因素协变，与治疗适应症无关。女性表现出更强的效应（利培酮治疗×性别相互作用t=2.32，p=0.02）。利培酮日剂量与BMI增加相关（每增加1 mg，效应量=0.28 SD（SE=0.07），t（419）=3.76，p<0.001）。与老年人群相似，利培酮治疗学龄前儿童与体重显著增加相关，有剂量效应的证据。研究结果提供了可以告知临床医生的关键数据。
Use of risperidone in preschool-aged children is growing, with rising concerns of adverse metabolic consequences. Longitudinal data on risperidone-related weight gain in preschoolers are scarce. We aimed to evaluate changes in body mass index (BMI) that are associated with risperidone treatment in preschoolers. We analyzed naturalistic, longitudinal data on 141 preschool children (112 boys, 29 girls) receiving psychiatric care. Mean patient age at baseline was 5.0 years (SD=0.8) and average follow-up period was 1.3 years (SD=0.8), with >8 mean BMI measurements per patient. We studied the effect of risperidone exposure (n=78) on age-and-sex-standardized BMI (BMI Z-score) implementing mixed models with random subject intercepts to account for repeated measures, covarying for multiple confounders including demographics, stimulant treatment and psychiatric diagnoses. We employed similar models to study dose and duration effects. Risperidone treatment was significantly associated with an increase in BMI (effect size of exposure=0.45 SD (SE=0.06), t (949)=7.7, p<0.001) covarying for stimulant exposure and other confounders, independent of treatment indication. Females exhibited stronger effects (risperidone treatment × sex interaction t=2.32, p=0.02)). Risperidone daily dose was associated with increase in BMI (for each additional 1 mg, effect size=0.28 SD (SE=0.07), t(419)=3.76, p<0.001). Similar to older populations, risperidone treatment in preschoolers is associated with significant weight gain, with evidence for dose effects. Findings provide critical data that can inform clinicians.
登录
查看更多内容
影响因子：
4.5
作者：
Parsons, Bruce;Allison, David B.;Siu, Cynthia
通讯作者：
Siu, Cynthia
DOI：
10.1016/j.jaac.2014.08.009
发表时间：
2014-11-01
影响因子：
13.3
作者：
Arango, Celso;Giraldez, Miriam;Parellada, Mara
通讯作者：
Parellada, Mara
影响因子：
17.7
作者：
Gothelf, D;Falk, B;Apter, A
通讯作者：
Apter, A
影响因子：
1.9
作者：
Kelly, DL;Conley, RR;Ushchak, CM
通讯作者：
Ushchak, CM
影响因子：
120.7
作者：
Correll, Christoph U.;Manu, Peter;Olshanskiy, Vladimir;Napolitano, Barbara;Kane, John M.;Malhotra, Anil K.
通讯作者：
Malhotra, Anil K.